Polypoidal choroidal vasculopathy is a complex eye condition affecting blood vessels beneath the retina, which can lead to vision loss if left unmanaged. Understanding treatment options—from standard injections to emerging therapies being tested in clinical studies—is essential for anyone facing this diagnosis and hoping to preserve their sight.

How Treatment Aims to Protect Your Vision

When someone is diagnosed with polypoidal choroidal vasculopathy, the main goal of treatment is to stop the abnormal blood vessels from leaking fluid or bleeding into the retina. This leakage is what damages the delicate tissue responsible for central vision—the part you use for reading, recognizing faces, or driving. Treatment tries to control these problems, prevent further damage, and, in many cases, actually improve vision that has already been affected.^[1]

The approach to treating this disease depends heavily on how far it has progressed and what symptoms are present. Some patients are diagnosed before they even notice vision problems, while others come in with sudden blurred vision or a blind spot in the center of their field of view. The stage of the disease, the location of the abnormal vessels, and how each patient responds to initial treatments all influence what doctors recommend next.^[2]

Medical societies and retina specialists have established guidelines for managing polypoidal choroidal vasculopathy based on years of clinical experience. These standard approaches have been proven to help stabilize vision and reduce complications. At the same time, researchers continue to investigate new treatments in clinical trials, testing innovative drugs and techniques that may offer even better results or require fewer visits to the doctor. This combination of proven therapies and cutting-edge research gives patients both immediate help and hope for the future.^[7]

Standard Treatments: What Doctors Use Today

The most widely used treatment for polypoidal choroidal vasculopathy involves injecting medication directly into the eye. These medications are called anti-VEGF drugs, which stands for anti-vascular endothelial growth factor. VEGF is a molecule your body produces that causes the abnormal vessels in this disease to leak fluid and bleed. By blocking VEGF, these injections help reduce the leakage and often decrease the amount of fluid or blood that has accumulated under the retina.^[1]

The injection procedure itself is called intravitreal injection, meaning the medicine goes directly into the vitreous gel inside the eye. While this might sound uncomfortable, the area is numbed beforehand, and the actual injection takes only seconds. Common anti-VEGF medications used for this condition include ranibizumab and bevacizumab, both of which work by targeting the same biological pathway that drives vessel leakage. Some newer anti-VEGF agents, like brolucizumab, have shown promise in clinical studies for maintaining vision gains while potentially extending the time between injections.^[7]

Successful treatment with anti-VEGF medication typically requires repeated doses. Many patients need injections as frequently as every four to six weeks to prevent the vessels from leaking again. This ongoing treatment schedule is necessary because the effects of each injection gradually wear off over time. During follow-up visits, your retina specialist will examine your eye, often using imaging tests to see if fluid has returned, and will decide whether another injection is needed.^[1]

Another established treatment is photodynamic therapy, often abbreviated as PDT. This approach uses a special light-sensitive medication called verteporfin, which is given through an intravenous infusion over about ten minutes. The drug travels through the bloodstream to the abnormal blood vessels in the eye. Then, a cold laser is applied to the retina and the layer beneath it. The laser activates the medication, which damages or destroys the abnormal vessels without generating heat.^[1]

Photodynamic therapy has been particularly effective at closing off the balloon-like polyps that characterize this disease. Studies have shown that PDT can achieve complete polyp regression in a high percentage of cases within the first year. However, the abnormal vessel network often persists, and polyps can come back over time. This means some patients need repeated PDT sessions to maintain the benefit. Despite this limitation, PDT remains an important tool, especially when combined with anti-VEGF injections.^[8]

Many retina specialists now use a combination approach, giving both anti-VEGF injections and photodynamic therapy together. This strategy takes advantage of the strengths of each treatment: PDT directly targets and closes the polyps, while anti-VEGF therapy reduces fluid leakage and prevents new abnormal vessel growth. Research suggests that combination therapy may lead to better visual outcomes and reduce the total number of treatments needed compared to using either method alone.^[11]

The duration of treatment varies widely from person to person. Some patients achieve stable vision after an initial series of injections and can be monitored with less frequent visits. Others require ongoing treatment for years. The disease can affect just one eye at first, but it often eventually involves both eyes, so regular monitoring of both eyes is crucial even if only one seems affected initially.^[1]

As with any medical treatment, there are potential side effects to consider. Anti-VEGF injections can occasionally cause eye pain, increased eye pressure, bleeding inside the eye, or infection, though serious complications are rare when the procedure is done properly. Photodynamic therapy can temporarily make the eye more sensitive to light, and repeated treatments may lead to areas of tissue loss or scarring in the retina. Your doctor will discuss these risks with you and take steps to minimize them.^[8]

In rare situations where there is a large hemorrhage that cannot be managed with injections or laser therapy, a surgical procedure called vitrectomy may be necessary. This involves removing the vitreous gel from the eye and clearing out the blood. Surgery is typically reserved for severe cases and is not a routine part of managing this condition.^[1]

Emerging Treatments in Clinical Trials

While standard treatments have helped many patients maintain or improve their vision, researchers are constantly working to develop better options. Clinical trials are testing new drugs, improved versions of existing medications, and entirely novel approaches to treating polypoidal choroidal vasculopathy. These studies take place in multiple phases, each with a specific purpose in understanding whether a new treatment is safe and effective.

Phase I trials focus primarily on safety. Researchers give the new treatment to a small group of people to see if it causes harmful side effects and to determine the best dosage. Phase II trials expand to a larger group and look more closely at whether the treatment actually works—for example, whether it reduces fluid in the eye or improves vision. Phase III trials compare the new treatment directly against the current standard of care in large groups of patients, providing the strongest evidence about how well it works and whether it should become widely available.^[7]

One area of active investigation involves longer-acting anti-VEGF medications. The need for frequent injections—sometimes every four to six weeks—places a significant burden on patients, requiring many clinic visits and time away from work or family. Newer molecules like brolucizumab have been designed to stay active in the eye for a longer period. Early trial results have shown that brolucizumab can maintain vision improvements while potentially extending the time between injections compared to older anti-VEGF drugs. It has also demonstrated superior anatomical outcomes, meaning better control of fluid and swelling in the retina.^[7]

Another promising therapy in development is faricimab. This drug takes a different approach by blocking two biological pathways at once: VEGF and another molecule called angiopoietin-2. By targeting both pathways simultaneously, faricimab aims to provide more complete control over the abnormal vessel growth and leakage that characterize polypoidal choroidal vasculopathy. Clinical trials are evaluating whether this dual-target approach can offer better vision outcomes or reduce treatment frequency even further.^[7]

A particularly innovative technology being tested is the port delivery system, sometimes abbreviated as PDS. This is a tiny implant placed inside the eye that slowly releases anti-VEGF medication over an extended period—potentially several months. If successful, this system could dramatically reduce the number of injections a patient needs, changing treatment from a monthly or bi-monthly injection to a refill procedure just a few times per year. Early trial data has been encouraging, though researchers are still working to confirm long-term safety and effectiveness.^[7]

Clinical trials for polypoidal choroidal vasculopathy are conducted in many locations around the world. Studies have been reported from research centers in the United States, Europe, and especially in Asian countries where this condition is more common. Eligibility for these trials typically depends on factors like the stage of disease, whether you have received prior treatment, your overall eye health, and sometimes your age or other medical conditions. If you are interested in participating in a clinical trial, your retina specialist can help you determine whether you might qualify and connect you with nearby study sites.

Some research is also exploring whether adjustments to photodynamic therapy—such as using lower doses of the light-sensitive drug or modified laser settings—can improve outcomes or reduce side effects. These “rescue PDT” or “add-on PDT” approaches are being tested in patients who initially received anti-VEGF therapy alone but did not respond well. Preliminary studies suggest that adding PDT at a later stage can still benefit some patients, though results may vary compared to using combination therapy from the start.^[15]

Most common treatment methods

• Anti-VEGF Injections
  • Medications like ranibizumab and bevacizumab injected directly into the eye to block vascular endothelial growth factor, reducing fluid leakage and bleeding from abnormal vessels
  • Typically administered every four to six weeks, with frequency adjusted based on disease activity
  • Newer agents like brolucizumab being studied for longer intervals between injections
• Photodynamic Therapy (PDT)
  • Intravenous infusion of verteporfin followed by cold laser application to activate the drug and destroy abnormal blood vessels
  • Particularly effective at closing polyp-like vessel dilations characteristic of the disease
  • Often used in combination with anti-VEGF therapy to enhance outcomes and reduce treatment burden
• Combination Therapy
  • Simultaneous use of anti-VEGF injections and photodynamic therapy to target both vessel leakage and polyp formation
  • May result in better long-term visual outcomes and fewer total treatments compared to monotherapy
  • Approach tailored to individual patient characteristics and disease severity
• Surgical Vitrectomy
  • Reserved for rare cases with large hemorrhages that cannot be managed with injections or laser
  • Involves removing the vitreous gel and clearing blood from inside the eye